Epitope-Targeted Autoimmune Therapy via Microbial Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune disorders, such as primary biliary cholangitis (PBC) and atopic dermatitis (AD), are limited by their non-disease specificity and broad spectrum approach, leading to side effects and secondary infections, with existing drugs often inhibiting immune system components non-selectively.
Innovation Solution
A method and system that involve collecting biological samples, extracting DNA sequences, identifying microbial taxa and pathogenic microbes, and generating artificial sequence constructs using refined molecular mimic epitopes linked with peptide linkers, adjuvants, and toll-like receptor ligands to enhance immunogenicity, allowing for targeted assessment and treatment of autoimmune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional broad spectrum drugs are used to treat autoimmune disorders, then immune response is suppressed, but non-selective inhibition leads to secondary infections and side effects
Solution Approach 1:
The invention segments the treatment approach by identifying and targeting specific microbial taxa and their epitopes associated with particular autoimmune disorders, rather than using broad-spectrum immunosuppression. This involves: (1) identifying disease-specific microbial taxa from biological samples, (2) mapping these taxa to specific autoimmune disorders using a disease microbe map, (3) identifying epitopes from these specific microbes, and (4) generating customized peptide constructs targeting only those specific epitopes. This segmentation enables selective treatment that suppresses only the immune response against pathogenic microbes while preserving responses to other microbes and preventing secondary infections.
Solution Approach 2:
The invention applies local quality by creating highly specific therapeutic peptides that target only the epitopes of specific pathogenic microbial taxa associated with a patient's autoimmune disorder. The customized peptide constructs contain precisely selected epitopic sequences from the identified pathogenic microbes, linked with specific adjuvants and TLR ligands tailored to the disease context. This localized targeting ensures that immunomodulation is confined to the specific pathogen-disease relationship without affecting other immune functions, thereby preventing broad-spectrum side effects and secondary infections.
2Reliability
If synthetic and biological drugs inhibit immune system components non-selectively, then immunogenic response is limited, but this approach leads to multiple side effects and increased infection risk
Solution Approach 1:
The invention segments the immunomodulatory approach by focusing on disease-specific microbial epitopes rather than broad immune suppression. The process involves identifying specific microbial taxa associated with the autoimmune disorder, mapping them to the disease, isolating epitopes from these specific microbes, and generating customized peptide constructs. This segmentation ensures that only the immune response against the specific pathogenic microbes is modulated, while other immune functions remain intact, thereby eliminating the side effects associated with non-selective immunosuppression.
Solution Approach 2:
The invention changes the fundamental parameter of treatment specificity by transitioning from non-selective immunosuppression to highly selective epitope-targeted therapy. The customized peptide constructs are designed with precise epitopic sequences derived from the patient's specific pathogenic microbes, combined with disease-appropriate adjuvants and TLR ligands. This parameter change from broad to specific targeting achieves effective disease control while minimizing harmful side effects, as the immune system is modulated only in the context of the specific pathogen-disease relationship.
3Adaptability or versatility
If conventional treatments use broad spectrum drugs, then multiple autoimmune disorders can be addressed, but the treatments are non-disease specific and lack precision
Solution Approach 1:
The invention segments the treatment approach into disease-specific modules by identifying the unique microbial taxa associated with each autoimmune disorder. The system creates separate disease microbe maps for different disorders (e.g., PBC, AD, IBD), and for each patient, identifies the specific microbial taxa present in their biological sample and maps them to the relevant disease. This segmentation enables precise targeting of each disease's specific pathogenic microbes while maintaining the ability to address multiple disorders through customized peptide constructs that can be tailored to each disease's microbial profile.
Solution Approach 2:
The invention introduces dynamics by making the treatment highly adaptable to each patient's specific microbial profile and disease context. The system dynamically identifies the patient's specific microbial taxa, maps them to the relevant autoimmune disorder(s), selects appropriate epitopes from these microbes, and generates customized peptide constructs with disease-specific adjuvants and TLR ligands. This dynamic, personalized approach maintains versatility in treating multiple autoimmune disorders while achieving high disease specificity through real-time adaptation to each patient's unique microbial-disease relationship.
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
This disclosure relates generally to methods and systems for handling autoimmune disorders. Effective handling techniques for treating the autoimmune disorders are limited. The present disclosure herein solves the problem of treating and handling the autoimmune disorders effectively by identifying the microbial epitopes present in the sample of the subject and by mapping the identified epitopes through the epitope knowledgebase. In the present disclosure, a biological sample is collected from a subject. Next, one or more DNA sequences are extracted, and microbial taxa and one or more pathogenic microbes are identified. Further, one or more microbial epitopes from the biological sample are identified. the autoimmune disorders of the subject are then assessed, based on at least one of (i) the one or more pathogenic microbes and (ii) the one or more microbial epitopes, using the epitope knowledgebase, to generate an artificial sequence construct, using one or more mimic epitopes.